Амилоидоз сердца: клиника, лечение, прогноз


Е.А. Жданова 1, В.В. Рамеев 2, С.В. Моисеев 1, 2, Л.В. Козловская 2, А.Ф. Сафарова 3

1 МГУ им. М.В. Ломоносова, Москва; 2 Кафедра терапии и профболезней ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития, Москва; 3 Российский университет дружбы народов, Москва
Амилоидоз сердца (АС) – одно из самых тяжелых проявлений системного амилоидоза. Современная классификация амилоидоза основана на различиях амилоидогенных белков-предшественников. Таких белков в настоящее время известно около 30; соответственно, выделяют около 30 форм амилоидоза. В статье освещаются морфология и патогенез амилоидоза, нарушения функции сердца, прогноз в зависимости от варианта амилоидоза, кардиальных нарушений, уровня в крови маркеров повреждения кардиомиоцита, а также наличия и тяжести внесердечных проявлений амилоидоза. Представлено лечение системного амилоидоза в зависимости от варианта заболевания.

Литература


1. Kyle R, Rajkumar S. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9(4):278–88.
2. Shah K, Inoue Y, Mehra M. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;66(17):1805–13.
3. Connors B, Davidoff R, Skinner M, Falk R. Senile systemic amyloidosis presenting with heart failure: A comparison with light chainassociated amyloidosis. Arch Intern Med 2005;165:1425–29.
4. Kyle R, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases.Semin Hematol 1995;32(1):45–59.
5. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141–57.
6. Steiner I. The prevalence of isolated atrial amyloid. J Pathol 1987;153(4):395–98.
7. Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: An arrhythmogenic substrate
for persistent atrial fibrillation. Circulation 2002;106:2091–97.
8. Ariyarajah P, Steiner I, Hajkova P, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009:113(2):132–37.
9. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006;15(5):287–90.
10. Ando Y, Nakamura M, Araki S. Transthyretinrelated familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057–62.
11. Gillmore J, Booth D, Pepys M, Hawkins N. Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart 1999;82:2.
12. Stangou A, Banner N, Hendry B, et al. Hereditary fibrinogen A-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 2010;115:2998–3007.
13. Hamer MJ, Janssen S, Van Ruswuk M, Lie K. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13:623–27.
14. Ha S, Kim W, Hwang S, et al. A case of systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. J Am Soc Echocardiogr 2009;22(5):542–47.
15. Frenzel H, Schwartzkopff B, Kuhn H, et al. Cardiac amyloid deposits in endomyocardial biopsies. Light microscopic, ultrastructural, and immunohistochemical studies. Am J Clin Pathol 1986;85(6):674–80.
16. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12.
17. Sedlis S, Saffitz J, Schwob S, Jaffe A. Cardiac amyloidosis simulating hypertrophic cardiomyopathy. Am J Cardiol 1984;53:969–70.
18. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141–57.
19. Siqueira-Filho A, Cunha C, Tajik A, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981;63:188–96.
20. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretinrelated cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143–53.
21. Liao R, Jain M, Teller P, et al. Infusion of light hains from patients with cardiac amyloidosis
causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594.
22. Shi J, Guan J, Jiang BЭ, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a noncanonical p38 MAPK pathway. PNAS 2010;107:4188–93.
23. Truran S, Gutterman D, Schlundt B, et al. Oxidative stress and apoptotic injury induced by amyloidogenic light chain proteins in human coronary artery endothelial cells. Circulation 2010;122:16538.
24. Perugini E, Rapezzi C, Piva T, et al. Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92: 343–49.
25. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;31:754–65.
26. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro–brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107: 2440–45.
27. Hisaki R, Yutani C, Imakita M, et al. Histopathological study of valvular deposits of amyloid protein in cardiac amyloidosis. J Cardiol 1996;31:7.
28. Vogelsberg H, Mahrholdt H, Deluigi C, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51:1022–30.
29. Volpi A, Cavalli A, Maggioni A, et al. Cardiac amyloidosis involving the conduction system and the aortocoronary neuroreceptors. Clinicopathologic. correlates. Chest 1986;90:619–21.
30. Ishikawa Y, Ishii T, Masuda S, et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int 1996;46(3):189–94.
31. Suwaidi JA, Velianou J, Gertz M, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999;131:838–41.
32. Whitaker D, Tungekar M, Dussek J. Angina with a normal coronary angiogram caused by amyloidosis. Heart 2004;90:54.
33. Perugini E, Guidalotti L, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–84.
34. Klein A, Hatle L, Taliercio C, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;16:1135–41.
35. Demir M, Paydas S, Cayli M, et al. Tissue Doppler is a more reliable method in early detection of cardiac dysfunction in patients with AA amyloidosis. Ren Fail 2005; 27:415–20.
36. Klein A, Hatle L, Taliercio C, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808–16.
37. Cueto-Garcia L, Tajik A, Kyle R, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 1984;59(9):589–97.
38. Falk R. Diagnosis and management of the cardiac amyloidosis. Circulation 2005;112(13):2047–60.
39. Feng Da Li, Edwards W, Oh J. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420–26.
40. Gertz M, Comenzo R, Falk R. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis.
Blood (ASH Annual Meeting Abstracts) 2004;104:754.
41. Klein A, Hatle L, Taliercio C. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808–16.
42. Kristen A, Perz J, Schonland S, Hegenbart U. Non-invasive predictors of survival in cardiac amyloidosis. Europ J Heart Failure 2007;9:617–24.
43. Dispenzieri A, Kyle R, Gertz M, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787–89.
44. Palladini G, Lavatelli F, Russo, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107: 3854–58.
45. Herlenius G, Wilczek H, Larsson M, Ericzon B. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64–71.
46. Lewis W, Skinner M, Simms R, et al. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplant 1994; 8:107–10.
47. Parrilla P, Ramirez P, Andreu L, et al. Long-term results of liver transplantation in familial amyloidoticpolyneuropathytypeI. Transplantation 1997;64:646–49.
48. Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore) 2006;
85(4):229–38.49. Nardo B, Beltempo P, Bertelli R, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc 2004;36:645–47.
50. Selvanayagam J, Hawkins N, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101–10.
51. Gertz M, Falk R, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channelblocking agents. Am J Cardiol 1985;55(13):1645.
52. Griffiths B, Hughes P, Dowdle R, et al. Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 1982;37:711–12.
53. Rubinow A, Skinner M, Cohen A. Digoxin sensitivity in amyloid cardiomyopathy. Circulation
idosis: two cases with digitalis sensitivity. Ann Intern Med 1961;55:989–94.
54. Austin B, Duffy B, Tan C, et al. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven car diac amyloidosis. Am J Cardiol 2009;103(10): 1429–33.
55. Comenzo R. How I treat amyloidosis. Blood 2009;114:3147–57.
56. Koch D, Sack F, Kristen A, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33:257–62.
57. Kristen A, Sack F, Schonland S, Hegenbart U. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Europ J Heart Failure 2009;11:1014–20.
58. Kpodonu J, Massad M, Caines A, Geha A. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart LungTransplant 2005;24:1763–65.
59. Kolstoea S, Mangionea P. Bellottia Trapping of palindromic ligands within native transthyretin prevents amyloid formation. PNAS 2010;107:20483–88.


Об авторах / Для корреспонденции


Жданова Е.А. – аспирант кафедры внутренних болезней ФФМ МГУ им. М.В. Ломоносова;
Рамеев В.В. – кандидат медицинских наук, ассистент кафедры терапии и профболезней МПФ ГБОУ ВПО “Первый МГ МУ им. И.М. Сеченова” Минздравсоцразвития РФ;
Моисеев С.В. – доктор медицинских наук, профессор кафедры терапии и профболезней МПФГБОУ ВПО “Первый МГ МУ им. И.М. Сеченова” Минздравсоцразвития РФ;
Козловская Л.В. – доктор медицинских наук, профессор кафедры терапии и профболезней МПФГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ;
Сафарова А.Ф. – кандидат медицинских наук, доцент кафедры пропедевтики внутренних
болезней медицинского факультета РУДН


Бионика Медиа